Breast Cancer

Aug 14, 2024

Breast Cancer Insights: Identifying Symptoms and Protecting Your Health

Aug 13, 2024

Roche’s HER2-Positive Breast Cancer Treatment Franchise

Aug 13, 2024

7 Most Common Myths About Breast Cancer Demystified

Aug 08, 2024

Novel Insights Into New Therapies for HR+/HER2- Breast Cancer

Aug 08, 2024

The Evolving Landscape of ER+ Breast Cancer Treatments

Aug 08, 2024

How HR+/ HER2-Breast Cancer Emerging Drugs Will Transform The Market?

Aug 08, 2024

HR+/HER2- Breast Cancer: Unveiling the Worldwide Advances and Strategies

Aug 08, 2024

Metastatic HER2-Positive Breast Cancer Landscape: What You Need to Know

Apr 02, 2024

AstraZeneca’s Voydeya FDA Approval; Akebia’s Vafseo FDA Approval; Bristol Myers Squibb’s Phase III YELLOWSTONE Trial Update; Astellas’ IZERVAY FDA Approval; AstraZeneca’s Truqap and Faslodex MHLW Approval

Mar 05, 2024

Bayer’s New Cardiology Drug Acoramidis; Two Datopotamab Deruxtecan Applications Validated in the EU; AbbVie and OSE Immunotherapeutics Announce Announces Partnership; vTv Therapeutics Makes Major Move With Cadisegliatin; A2 Bio Scores FDA Orphan Drug Designation for its Therapy, A2B530; FDA Fast Track Designation for AlloNK® in Lupus Nephritis

Newsletter/Whitepaper